Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still hodling these ONVO hoping SpaceX buys them out and then it's "To da moon!"
Think they'll do the same divy as last time?
I haven't seen yet what percentage of TSLA income is generated by subscription services like FSD etc... I would think that the majority of Tesla customers are also subscribed to some level with Tesla, and I wonder if other car companies have a bigger challenge acquiring those subscription type customers. In other words, Tesla gains both a primary customer and then a residual customer at the same acquisition costs. I don't feel like any new car I ever bought warranted an add on subscription after any trial period. But I definitely would subscribe to Tesla services if I bought a Tesla to retain it's value. Does Tesla charge for over the air updates?
AT this rate, it doesn't matter what happens, once the BTC limit gets really close, that's when this thing goes nuts. The best part of owning a miner like RIOT versus the actual digital currency, is that the miner can just change software to what ever they want to mine, from BTC to Etherium or w/e. The thing I like about Riot is even if the cost of mining drops enough, they can still make money selling back energy to the grid. They've got some really handsome energy deals.
Another thing to consider, what would happen if RIOT decided to give a dividend in BTC to its shareholders? They run in the green profit wise, and smart companies that make profits give out divvies. Have they partnered with a wallet company yet? The regulations coming up might just back them into needing an exchange since they might have to report as one in any case.
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk
BY GlobeNewswire
— 12:00 PM ET 01/10/2022
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (ONVO) , today released its first detailed response to the lawsuit Cellink filed against it in Delaware court in 2021. At issue in this lawsuit is whether Cellink is infringing Organovo (ONVO) patents. Organovo (ONVO), as one of the earliest and most prominent 3D bioprinting companies, has built a strong and foundational patent portfolio in the space. Organovo (ONVO) believes that Cellink, as a newer company with limited patent filings, has moved forward without regard to its patents and now is at risk of owing significant license fees and royalties to Organovo (ONVO).
Organovo (ONVO) is accusing Cellink of infringing several of Organovo’s patents, and thus Organovo (ONVO) filed counterclaims to the Delaware suit on Friday, January 7, 2022, and asserted an additional patent against Cellink. With trial set for April 2023, Organovo (ONVO) looks forward to a speedy outcome to the case, with the possibility to gain a damages award that might be tripled if Cellink is determined to have willfully infringed Organovo’s patents.
Organovo (ONVO) Executive Chairman Keith Murphy commented on the legal proceedings, “Organovo has a powerful foundational patent portfolio in the 3D bioprinting space. Cellink launched itself and grew to $1.5B market capitalization on the basis of bioprinting revenue streams Organovo (ONVO) now contends were achieved through unauthorized use of Organovo’s intellectual property. We look forward to the legal process to award Organovo (ONVO) its due share of the revenue that Cellink has only achieved due to such patent infringement. We believe that this revenue, and IP licensing revenue more broadly in the bioprinting space, will properly reward our investors for the early investment in intellectual property.”
Third parties recognized Organovo’s bioprinting IP as foundational and innovative as far back as 2015, before Cellink announced its first printer. Organovo (ONVO) welcomes the opportunity to hold Cellink accountable for the damages Organovo (ONVO) has incurred due to Cellink’s unauthorized use of Organovo’s IP.
Rumor has it that Apple is going to pay this money off before the end of the year. $500 million cash plus fees and interest... man this should go nuts. I'm thinking back up to $8 or higher when it does?
--Street Color: Unconfirmed Social Media Chatter Claims Possible Acquisition of Sundial Growers, Tilray Mentioned as Potential Suitor
BY MT Newswires
— 10:26 AM ET 10/21/2021
Why doesn't Apple just buy Virnetx Holdings and all their IP for 1$ billion, then they get the IP, and all the cash from the last settlement.
NYSE To Commence Delisting Proceedings Against Just Energy Group Inc
BY Reuters
— 4:25 PM ET 03/09/2021
OTC next, then an interesting ride?
Following Unprecedented Winter Storm in Texas and Protection Granted under the CCAA in Canada, Just Energy Receives Chapter 15 Bankruptcy Protection in U.S.
BY GlobeNewswire
— 3:53 PM ET 03/09/2021
Now what happens? Delisting then OTC roller coaster? This could be interesting
Nearly 2 billion in revenue on the OTC... hmmmm
"Our PrivacyLok launched last week, and is available right now, and SafeVchat launches next Monday March 8th. "
On November 23, 2020, Organovo Holdings, Inc. (the “Company”) entered into two Lease Agreements (the “Lease Agreements”), by and between Company and San Diego Inspire 1, LLC, pursuant to which the Company will temporarily lease approximately 3,212 square feet of office space (the “Temporary Lease”) located at 11585 Sorrento Valley Road, Suite 106, San Diego, California 92121 (the “Temporary Premises”), and will permanently lease approximately 8,051 square feet of office space (the “Permanent Lease”) at 11555 Sorrento Valley Road, Suite 100, San Diego, California 92121 (the “Permanent Premises”) once the tenant improvements for the Permanent Premises have been completed and it is ready for occupancy.
Something going on here. 8-k out, here's an excerpt:
RECITALS
WHEREAS, the Company’s Board of Directors (the “Board”) previously determined that it would be in the best interests of the Company and its stockholders, to maximize stockholder value, for the Company to complete a merger transaction (the “Merger”) with Tarveda Therapeutics, Inc. (“Tarveda”).
WHEREAS, the Company’s stockholders did not approve the Merger at a Special Meeting of Stockholders held on April 7, 2020 (the “Special Meeting”) to approve such transaction, and as a result, the Company terminated its agreement with Tarveda.
WHEREAS, following the Special Meeting, the Board continued to reach out to the Company’s two largest institutional stockholders, each of whom voted against the Merger at the Special Meeting, seeking to engage them on the Company’s strategic alternatives and how to maximize stockholder value.
WHEREAS, one of the Company’s engaged stockholders indicated its desire for the Board to consider opportunities in the 3D bioprinting field and suggested that the Board should speak with Mr. Murphy for potential business ideas.
WHEREAS, Mr. Murphy submitted an initial solicitation notice on May 31, 2020 (the “Stockholder Nomination”), providing notice of his intention to nominate Mr. Murphy, Douglas J. Cohen and Mr. Stern as nominees for election to the Board at the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”).
WHEREAS, Mr. Murphy has engaged in discussions with the Company regarding the composition of the Board and the Company’s business, financial performance, and his strategic plan for the Company.
WHEREAS, the Board has reviewed and approved the qualifications of Mr. Murphy and Mr. Stern (the “Murphy Appointees”) to serve as directors on the Board in accordance with the criteria for service on the Board as set forth in the Company’s Corporate Governance Guidelines.
WHEREAS, the Board, based on the information certified to the Company by the Murphy Appointees, has determined that Mr. Stern qualifies as an “Independent Director” under the continued listing standards of the Nasdaq Stock Market (the “Nasdaq Rules”), but that Mr. Murphy does not qualify as an “Independent Director” under the Nasdaq Rules based on his position as an executive officer, director and controlling stockholder of Viscient Bio, Inc. (“Viscient”) with which the Company has entered into business transactions.
WHEREAS, Mr. Murphy has designated Doug Cohen, David Gobel and Alison Milhous to be appointed to the Board by the Company’s existing Board based on the vote of the Company’s stockholders on an advisory proposal at the 2020 Annual Meeting as set forth in this Agreement (each, an “Advisory Nominee,” and collectively, the “Advisory Nominees”).
WHEREAS, the Board has approved the qualifications of each of the Advisory Nominees to serve on the Board.
WHEREAS, the Company and Mr. Murphy each believe that it is in the best interests of the Company and its stockholders to enter into this Agreement and to resolve the composition of the Board and certain other matters set forth in this Agreement.
Batteries. Present day battery technology is profitable for Tesla now. Advances only increase profitability from here. As a stock, TSLA will always have SpaxeX as a backstop as long as Elon has control of both. If ever Elon Musk et al ever take SpaceX public, it would only make sense to roll it into Tesla. There is already a lot of synergy with those two companies. I still would love to see Elon buy up Organovo Holdings ONVO. Putting 3D organ printers into space would pay for itself in lives alone.
Have seen the same thing as you here with ZSAN. I went short at .99 and back in down hereunder a buck
This is legit disruptive shit here. Seen many such little biotecks get bought out. THLD, PTIE, IPCI to name a few.
Isn't blockchain supposed to be self regulating? Kinda the point? Anyway: Has anyone else noticed this could get some exposure soon?
Riot Blockchain Engages Gateway to Lead Investor Relations Program
BY PR Newswire
— 8:45 AM ET 02/13/2020
CASTLE ROCK, Colo., Feb. 13, 2020 /PRNewswire/ -- Riot Blockchain, Inc. ("Riot" or the "Company"), a cryptocurrency miner that focuses on bitcoin, has appointed Gateway Investor Relations, a leading strategic financial communications and capital markets advisory firm, to provide investor relations and consulting services to the company.
Riot Blockchain Logo (PRNewsfoto/Riot Blockchain, Inc.)
Gateway is a strategic financial communications firm specializing in advising public companies across a broad range of industry classifications. Founded in 1999, the firm provides high-level capital markets consulting, corporate communications, and investor outreach. The firm is also specifically experienced in helping technology companies access and effectively navigate the U.S. capital markets.
Gateway will work closely with Riot management to develop and deploy a comprehensive capital markets program. Gateway will also assist in organizing non-deal roadshows and securing invitations to select financial conferences (including the Gateway Conference) for Riot management over the upcoming months.
About Gateway Investor Relations
Gateway (formerly Liolios) is a leading strategic financial communications and capital markets advisory firm. For more than 20 years, the firm has delivered superior performance in strategic consulting, corporate messaging and positioning, investor awareness, and analyst and financial press coverage. Gateway executives have extensive experience in capital markets and financial communications, and represent clients in a wide range of industries, including technology, consumer, industrials, financial services, and business services. To learn more, please visit www.gatewayir.com.
About Riot Blockchain ( RIOT)
Riot Blockchain ( RIOT) specializes in cryptocurrency mining. The Company's operational focus consists of mining bitcoin. Riot also holds non-controlling investments in blockchain technology companies. Riot is headquartered in Castle Rock, Colorado, and the Company's mining facility is located in Oklahoma. For more information, visit www.RiotBlockchain.com.
Safe Harbor
The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the sections entitled "Risk Factors," copies of which may be obtained from the SEC's website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/riot-blockchain-engages-gateway-to-lead-investor-relations-program-301004185.html
SOURCE Riot Blockchain, Inc. ( RIOT )
It will certainly be interesting to see who ends up with this IP after the merger. Surely they'll sell it off, or spin it off. Maybe keepo rights to it so they can print test tissues. Otherwise, I wonder if there are others out there taking notice of this I.P portfolio, other than Keith I mean.
Investors taking new positions in this ticker.
Form SC 13G/A Vuzix Corp Filed by: HIRSCHMAN ORIN
BY 10K Wizard
— 6:05 AM ET 01/16/2020
I also noticed two top insiders buying more as well.
Form 4 Vuzix Corp For: Jan 13 Filed by: Travers Paul J
BY 10K Wizard
— 10:07 AM ET 01/14/2020
Form 4 Vuzix Corp For: Jan 15 Filed by: Kay Edward William Jr.
BY 10K Wizard
— 10:07 AM ET 01/16/2020
There is only one reason I know of for insiders to buy their own stock. They know it's going higher. Looking at the 5 year chart this likes to settle around $6, so under $2 seems a bit oversold.
If/When VUZI ever reports a profit again, kiss single digits g'bye. This could fly past $10 and right into the $20 before settling back down. If one of the many tie-ups they've scored hits hard, that could happen quickly, if it hasn't already. VR seems like one of those things that's just holding its breath waiting to hit popularity.
We'll see!
Got very quiet here. Expecting this to get pumped again soon due to this?
Brian Keith helped found this Co. He must want it back?
What does this 8-K mean?
Amendment to Bylaws of Organovo Holdings, Inc.
October 9, 2019
ARTICLE XI – EXCLUSIVE FORUM
Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state or federal court located in the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the corporation, (2) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or stockholder of the corporation to the corporation or the corporation’s stockholders, (3) any action arising pursuant to any provision of the DGCL, or these Bylaws or the corporation’s certificate of incorporation (as either may be amended from time to time), or (4) any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the corporation shall be deemed to have notice of and consented to the provisions of this Article XI. Notwithstanding anything otherwise to the contrary herein, the provisions of this Article XI will not apply to suits brought to enforce a duty or liability created by the federal securities laws or any other claim for which the federal courts have exclusive jurisdiction.
So the 2 factor authentication patent lawsuit is back on the table? This could get interesting again. Might be worth picking up a few more down here. News could be likely to send this back over the pennies again like the Microsoft lawsuit did?
BRIEF-Zosano Pharma Corp - Co To Terminate Purchase Agreement With Lincoln Park Capital Fund LLC
BY Reuters
— 4:00 PM ET 08/26/2019
This doesn't seem to have influenced investors or traders in this stock. What are the implications?
Scientists bioprint living tissue in a matter of seconds
https://www.engadget.com/2019/08/24/bioprint-living-tissue-in-seconds/?guccounter=1&guce_referrer=aHR0cHM6Ly9uZXdzLmdvb2dsZS5jb20v&guce_referrer_sig=AQAAACvjUxV3WY-gh58Usd7wl07d3-BeBHod_PT4V7EM9AsTSKR8Y4tfVs3JxWBA9QXVgtOTKGLBs-1GBAqBb-JN2TJ_6qWm4t8pnRwrNrCzITMdJIDZC1e4WROUdogJVtLlrnyB7_a3ohlxZKWa2rwJFzuMoxM6-nPBE4Uhqqc9F2Vw
BY GlobeNewswire
— 9:00 AM ET 08/07/2019
Organovo to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. today announced that it has engaged Roth Capital Partners (“Roth”) as its financial advisor to assist in the exploration of strategic alternatives. This decision was reached by Organovo’s board of directors after concluding that the Company had not generated decisive scientific data supporting the prolonged functionality and therapeutic benefit of its lead therapeutic liver tissue candidate, and that the necessary redevelopment of the tissue would require significant time, additional resources and development risks, and would likely not provide sufficient return on investment for the Company’s stockholders. To support the range of strategic alternatives being explored, the Company is also implementing a restructuring plan to significantly reduce expenses associated with its lead program in order to preserve cash.
Archinaut snags $73 million in NASA funding to 3D-print giant spacecraft parts in orbit.
https://techcrunch.com/2019/07/12/archinaut-snags-73-million-in-nasa-funding-to-3-d-print-giant-spacecraft-parts-in-orbit/
Won't be long! ONVO!
That's some cutting edge tech. Bioprinting in zero G, or microgravity, also solves a ton of 3D bioprinting issues. For that matter, any material being 3D Printing in zero G has enormous possibilities. Anyone 3D printing at 1G on earth knows it is a pain in the neck.
Does this SOLY drop on news and rise on rumor? Will be interesting to see on the 15th.
Shares Outstanding 130,227,000
I hope SpaceX notices Organovo (ONVO). They are working with a pretty decent brain trust on this 3D printing human organs thing. If it turns out that doing so in null G in orbit makes a lot of sense for printing compete organ(s) SpaceX has the potential to make that type of orbital mission possible.
What a ride. Looks like the number of brains working on this just jumped considerably. These guys are so ahead of everyone else. Two fronts, kidney and liver. And it seems like they know how to grow ONVO business. Under a buck... just sayin...
Everyone keeps wondering what the next big thing is going to be. I think this may be one, and pretty soon too. It certainly has taken patience with ONVO, but eventually, I feel like my investment here will pay off quite nicely. I just keep averaging my costs down while accumulating. But that's just me being patient. I do wonder though, will Organovo ever go into the business of selling their 3D bioprinters? There's bound to be a huge market for them, especially after they've passed a few clinical trials. Watching SpaceX having continued success with their rocket technology, enforces my opinion that this 3D bioprinting technology could be just as close to being matured into a money maker. It's going to take time, but you just never know when a disruptive technology like this will gain the right attention. Here's a message to Elon Musk: 3D bioprinted human organs in Space!
Just sayin...
Seems funny being the only one posting here. I just hope the right people are reading this. I'll say it again, as a ONVO stock holder, I would love to see Organovo team up with SpaceX to develop 3D bioprinting organs in zero G. Or at the least, some clever company with the talent and foresight to come forward and make this happen. Someone will eventually. The question is, whom?
And just in case someone from Tesla (TSLA), like Elon Musk, or someone from SPaceX reads these posts, I would like to call attention to a win win scenario that could result from a partnership between Tesla, SpaceX and Organovo (ONVO). Tesla's AI, SpaceX's reusable rockets, and Organovo's 3D human tissue Novojet technology could make 3D printed human replacement organs in zero gravity a reality in our lifetime.
It would work like this: A zero G modular lab is set up in orbit. A Falcon booster brings up a module with raw materials (Bio Ink DNA matched to a patient), swaps out the module(s) and brings back completed organs, landing near a major hospital where the patient(s) are awaiting their organs for transplant. A self driver delivery Tesla picks it up and delivers said organs. Rinse and repeat.
Please do this Tesla, SpaceX and Organovo, I'm going to need some replacement organs some day, we're not getting any younger!
What are the chances that SpaceX will be going public this year? I think it's great how much Musk is making from that rocket company
Gives him deep enough pockets to patch any holes TSLA may ever develop. Feel pretty safe with my money here. We'll see in a few years if I'm justified in that, but for now I see nothing to stop Tesla from being the leading car maker of the 21st century, where eventually it'll be illegal to operate a car without an AI driver. Cars don't cause crashes! Humans cause car crashes!
Might be the last chance to get in under $300. The last Elon faux paux resulted in a very nice buying opportunity. This one doesn't look like it'll have the same level of effect. The shorts are probably like, fool me once...
My guess would be that maybe they have gotten rich while at Tesla, and left to do their own rich guy thing. How many of Alphabet (Google) upper management has gone off to do the rich guy thing? Or Microsoft? or Amazon?
just sayin...
Just in case anyone missed the implications of adding Ms Beaver to the BOD.
It looks evident the BOD is getting their ducks lined up for Organovo to get acquired.
On February 19, 2019, the Board of Directors (the "Board") of Organovo Holdings, Inc. ( ONVO ) (the "Company") authorized and approved an increase in the size of the Board from eight (8) to nine (9) members and appointed Carolyn Beaver to the Board as Class I Director.
Ms. Beaver has over 30 years of audit and financial management experience. She previously held several positions at Sequenom Inc., a life sciences testing company, including Chief Financial Officer and Senior Vice President from March 2015 to October 2016, Chief Financial Officer from June 2014 to March 2015 and Vice President and Chief Accounting Officer from June 2012 to March 2015. (see below about Sequenom)
Ms. Beaver was previously Corporate Vice President and Controller of Beckman Coulter, Inc., a biomedical laboratory instrument and test company, from August 2005 until June 2012, and was named Chief Accounting Officer in October 2005, a position she held until July 2011, following the acquisition of Beckman Coulter, Inc. by Danaher Corporation.
Ms. Beaver was a director of Commerce National Bank, chair of its audit committee and a member of its asset/liability committee from 2005 until the bank was acquired in 2013.
LabCorp Completes Sequenom Acquisition
Sep 07, 2016
NEW YORK (GenomeWeb) – Laboratory Corporation of America announced today that it has completed its acquisition of Sequenom.
ORGANOVO APPOINTS NEW BOARD MEMBER
SAN DIEGO – February 20, 2018 – Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member. Ms. Carolyn Beaver, former Chief Financial Officer of Sequenom Inc., will join Organovo’s board, effective immediately. Ms. Beaver’s appointment increases the number of Organovo directors to nine.
“Carolyn brings significant audit and financial management expertise to our board,” said Taylor J. Crouch, CEO, Organovo. “Her senior leadership experience across the life sciences sector adds to the strength of our already outstanding board, and I look forward to tapping into her impressive skill set as we drive our lead program toward the clinic over the next two years.”
Ms. Carolyn Beaver has over 30 years of audit and financial management experience. She previously held several positions at Sequenom Inc., a life sciences testing company, including Chief Financial Officer and Senior Vice President from March 2015 to October 2016, Chief Financial Officer from June 2014 to March 2015 and Vice President and Chief Accounting Officer from June 2012 to March 2015. Ms. Beaver was previously Corporate Vice President and Controller of Beckman Coulter, Inc., a biomedical laboratory instrument and test company, from August 2005 until June 2012, and was named Chief Accounting Officer in October 2005, a position she held until July 2011, following the acquisition of Beckman Coulter, Inc. by Danaher Corporation. She also served as interim Chief Financial Officer of Beckman Coulter from July 2006 through October 2006. Ms. Beaver was a director of Commerce National Bank, chair of its
audit committee and a member of its asset/liability committee from 2005 until the bank was acquired in 2013. Ms. Beaver served as an audit partner with KPMG LLP from 1987 to 2002. She was named a director and member of the audit committee of MaxLinear, Inc., a high-performance broadband and networking semiconductor company, in December 2018. Ms. Beaver received a Bachelor of Science degree in Business Administration from California State Polytechnic University, Pomona.
PRE-INVESTIGATIONAL NEW DRUG MEETING WITH FDA EXPECTED TO BE HELD IN CALENDAR 2019
PLANS TO BEGIN IND-ENABLING TOXICITY STUDY FOR ITS LEAD PROGRAM IN SECOND HALF OF CALENDAR 2019
BRIEF-Organovo Affirms Key Clinical Development Goals, Reports Fiscal Third-Quarter 2019 Results
BY Reuters
— 4:20 PM ET 02/07/2019